Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Cytokinetics (CYTK) Tops Q4 EPS by 4c, Revenues Beat; Offers FY19 Revenue Mid-Point Guidance Above ConsensusFebruary 21, 2019 4:02 PM Amgen, Cytokinetics And Servier Announce Start Of METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart FailureFebruary 21, 2019 8:30 AM